Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different-dose tigecycline in critically ill patients with multidrug-resistant bacterial infection
ChiCTR2100046950Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tigecycline in bacterial disease and Infection (3 arms), sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoints: Tigecycline serum drug concentration, White blood cell count and 6 more. Started Jun 2019; status: recruiting.
02
Drugs
tigecycline
03
Conditions
bacterial diseaseInfection
Beyond the preview
Go deeper on ChiCTR2100046950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046950.